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Safety and potential efficacy of gemfibrozil
as a supportive treatment for children with
late infantile neuronal ceroid lipofuscinosis
and other lipid storage disorders
Kyeongsoon Kim1, Hynda K. Kleinman2,3*, Hahn-Jun Lee2 and Kalipada Pahan4
Abstract
Neuronal Ceroid Lipofuscinosis (NCL), also known as Batten disease, is a group of genetically distinct lysosomal disorders
that mainly affect the central nervous system, resulting in progressive motor and cognitive decline primarily in children.
Multiple distinct genes involved in the metabolism of lipids have been identified to date with various mutations in this
family of diseases. There is no cure for these diseases but some new therapeutic approaches have been tested that
offer more hope than the standard palliative care. Many of the therapeutic advances require invasive procedures but
some progress in slowing the disease has been found and more options can be expected in the future. We also review
the literature on children with disease/conditions other than NCL for the non-invasive use, safety, and tolerability of a
lipid-lowering drug, gemfibrozil, as a potential treatment for NCLs. Gemfibrozil has shown efficacy in an animal model
of NCL known as CLN2 (late infantile classic juvenile) and has been shown to be safe for lowering lipids in children.
Among the 200 non-NCL children found in the published literature who were treated with gemfibrozil for NCL-related
problems, only 3 experienced adverse events, including 2 with muscle pain and 1 with localized linear IgA bullous
dermatitis. We conclude that gemfibrozil is safe for long-term use in children, causes minimal adverse events, is well
tolerated, and may delay the progression of NCLs. Gemfibrozil may potentially be an alternative to more invasive
therapeutic approaches currently under investigation and has the potential to be used in combination with other
therapeutic approaches.
Keywords: Batten disease, NCL, Gemfibrozil, Lipofuscinosis, Central nervous system, Lysosome biogenesis, TPP1, Lopid,
CLN2, Children
Background
Neuronal Ceroid Lipofuscinsosis (NCL), also known as
Batten disease, is a group of inherited neurodegenerative
diseases affecting approximately 1–4 children per
100,000 live births [1–4]. NCLs mainly affect children
and generally start with seizures and/or a loss of vision
at an early age followed by rapid motor and cognitive
decline leading to premature death.
NCLs are generally autosomal recessive, and the fre-
quency of these diseases varies by genetic mutation and
by country. To date, over 400 different mutations are
found in multiple genes [2, 3, 5]. A data-base contains
information on the specific mutations identified to date
(http://www.ucl.ac.uk/ncl).
Most of the proteins encoded by the mutated genes
are lysosomal, including soluble enzymes (CLN1/PPT1,
CLN2/TPP1, CLN10/CTSD, CLN13/CTSF) or a soluble
lysosomal protein (CLN5) [2]. One protein is also
present in the secretory pathway (CLN11). In addition,
there are trans membrane proteins (CLN3, CLN6,
CLN7/MFSD8, CLN8, CLN12/ATP132A) and two cyto-
plasmic proteins that associate peripherally with mem-
branes (CLN4, CLN14). Two trans membrane proteins
(CLN6 and CLN8) localize in the endoplasmic reticulum
while others (CLN4/DNAJC5 and CLN14/KCTD7) are
cytoplasmic and associate with cell membranes.
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The functional substrates of these proteins are not
known, and the major functions of the trans membrane
proteins in general and in the disease etiology are un-
clear [6]. The age of onset, severity, and rapidity of pro-
gression differ for each of the mutations in these genes
and for the different mutations within each gene [2].
Thus, a complex family of related lipid storage diseases
with different genetic etiologies forms the NCL family.
Such diversity in the genes and in the gene mutations
can make finding a comprehensive therapeutic treatment
challenging for the largely unknown and complex
pathophysiology of the NCLs.
Therapeutic approaches for NCLs
There is no cure for NCLs at this time. The standard of
care is generally to minimize symptoms, especially sei-
zures. Many new therapies are emerging and hopefully
some will halt or slow disease progression but none are
likely to reverse the damage [7–9]. Based on a systematic
search of the literature and clinicaltrials.gov, several ap-
proaches offer promising therapeutic strategies, includ-
ing gene therapy, stem cell therapy, enzyme replacement
therapy, anti-inflammatories, and small molecules. All
are being tested on animal models and in some cases the
studies have progressed to early stage human trials. Nat-
ural and genetically modified mice and other animal
models, including large animals, such as pigs, sheep,
cows, and dogs, have greatly helped in determining
delivery mode, ability to cross the blood-brain-barrier,
dosing amount, frequency of dosing, and efficacy. Unfor-
tunately at this time, the work is primarily experimental
and invasive in many cases but proof of concept and im-
proved treatment regimens offer considerable hope. The
complexity and number of genes and mutations affected
is problematic in developing and testing new treatments.
Below are some examples of the types of therapeutic
approaches and their success to date. One can expect
many more treatment options with additional emerging
technologies.
Viral-mediated gene therapy for NCLs generally
involves the use of a viral vector carrying a normal form
of the mutated gene localizing in the central nervous
system [10–12]. When the virus enters the cells in the
brain, the cells then express normal copies of the mu-
tated protein that are taken up by the nearby cells. This
approach is attractive because it offers the potential for a
lifelong cure that does not require multiple repeated
treatments. It therefore is less invasive for the patient
than other approaches. There are many additional
advantages to viral vectors, including their tropism for
certain cells. However, these vectors, particularly the
adeno-associated viruses, do induce an immune
response. Lentiviral vectors have a reduced immune
response but their integration can be non-specific and is
limited to the site of injection [13]. One concern is the
lack of potential therapeutic efficacy for the lipid accu-
mulation in organs outside of the brain if the vector is
delivered to the brain. Using TPP1-deficient dogs treated
with an adenoviral vector containing TPP1, it was found
that the protein was increased in both the heart and
spleen but not in the kidney or liver [14]. Additional
studies are needed to optimize the efficacy and reduce
the potential immune response issues for viral vectors.
Various animal models have been tested with adeno-
associated viral vectors and increased survival along with
improved motor skills were observed [12]. Based on
these successful results, phase 1 safety trials (NCT
01161576, NCT01414985, and NCT00151216) of an
adeno-associated viral gene transfer vector for CLN2 in
the brain of children with late infantile NCL are on-
going, and 1 phase 1/2a (NCT02725580) for CLN6 with
scAAV9 has begun.
Enzyme replacement therapy involves preparing a
large amount of protein based on the normal version of
the mutated gene usually by recombinant methods and
injecting the recombinant protein (rhTPP1) into the tis-
sues, namely the brain for CNL2 [15–21]. The disadvan-
tages are that the blood-brain-barrier has to be
considered and there is a need for repeated injections.
Mice, dogs, and monkeys tested with various doses and
different routes of administration have provided positive
results and led to a clinical trial for late infantile NCL
(NCT01907087) that is now complete. It is exciting that
this trial has reported positive results for CLN2 protein
replacement and that the treatment with recombinant
TPP1 (also known as cerliponase alpha or Brineura) was
recently approved by the FDA. The treated patients
showed a significant efficacy in the disease rating scale
relative to that of natural history controls i.e. disease
progression was reduced in the treated children. The
disadvantages are that for this level of success, the pa-
tients had 1 site in their brain injected every other week
for 48 weeks. The procedure is not a cure and is invasive
and costly. Enzyme replacement therapy is likely to work
for the patients with the mutated and soluble lysosomal
proteins (CLN1/PPT1, CLN2/TPP1, CLN10/CTSD,
CLN13/CTSF, CLN5) but not for the patients with mu-
tated trans membrane and membrane-associated pro-
teins (CLN3, CLN4/DNA JC5, CLN 5, CLN6, CLN7/
MFSD8, CLN8, CLN14) [4]. Further studies on the dos-
ing amount and frequency, penetration through the
blood-brain-barrier, etc. are needed for optimization of
enzyme replacement therapy for NCLs.
Small molecule therapy involves enhancing activity by
correcting signaling or cellular metabolic pathways and
includes drugs that may act as pharmacological chaper-
ones, receptor modulators, and immune modulators or
reduce the amount of substrate [7, 8, 22, 23].
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Chaperones have the advantage that they are small, can
distribute widely, and can be taken orally [22, 23]. The
disadvantage is that such drugs will have limited use as
they act only on proteins where the mutation is not near
the active site but has caused a protein-folding problem.
The use of receptor modulators is potentially a powerful
approach, and improvement in the motor function of a
mouse model of CLN3 has been observed with an
AMPA antagonist [7, 24–26]. However, substrate reduc-
tion therapy with Cystagon has not been successful
(NCT00028262) in reducing disease progression [27].
Immune modulators are a logical approach as inflamma-
tion precedes the neurodegeneration observed in NCLs.
Several immune modulators have been tested without
success [28, 29]. A recent phase 2 trial (NCT01399047)
for CLN3 with mycophenolate given for 8 weeks has yet
to report the results. These small molecule therapies will
likely become relevant as advances are made in delivery
and in their use in other neurodegenerative diseases.
Stem cell therapy, including bone marrow cells, is
aimed at having the stem cells incorporate into tissues
and provide a source of non-mutated proteins. It is also
possible that the stem cells will regenerate the tissue that
has been damaged or lost. Stem cell therapy is thus at-
tractive because it offers the potential to replace dam-
aged or lost tissue in advanced patients. To date,
hematopoietic stem cell transplantation has shown no
efficacy in NCL patients [30, 31]. Neural stem cells have
also been tested in a mouse model of CLN2 and some
reduction in the storage of lipids was found [32]. Fetal
neural stem cells have been injected into two locations
in the brain as part of a safety and efficacy trial in
patients with advanced disease (NCT00337636).
Immunosuppression was used to reduce complications.
The results of the trial showed good tolerability and an
increased production of CLN2 enzyme but additional
studies are needed to optimize this approach for
reducing or reversing disease progression.
In summary, there are many different types of
approaches being used to develop therapeutics for the
NCL family of diseases. These studies have been aided
greatly by the use of small and large animal models of
the different diseases [33, 34]. The exciting success of
enzyme replacement therapy for CLN2 is a proof of
principal that replacing the mutated soluble and secreted
proteins will be effective and offers the families and chil-
dren a treatment option. Marked progress is being made
with other treatment approaches, such as gene therapy
and stem cells, as well as with small molecules [8].
Furthermore, new technologies, such as gene editing
and new classes of treatments, are emerging that may
advance some of these treatments. Because of the
complex genetics of the NCLs, these existing approaches
may be limited in applicability to each condition. The
devastating effects on young children are rapid, often
not immediately diagnosed so that the disease has pro-
gressed at the time of diagnosis in many cases, and the
invasive nature of the majority of these treatments can
deter the families from opting to try them. Recently, a
simple and safe lipid lowering drug, gemfibrozil, has
shown efficacy in cells and in an animal model and may
offer the patients a non-invasive option for treatment
either alone or in combination with other emerging
treatments [35–49].
Gemfibrozil (Lopid)
Gemfibrozil is a member of the fibrates group of drugs
that lower lipid levels [35]. It was originally shown to
lower lipids in animals in the 1960s and was approved
by the FDA in 1976 for human use to reduce serum
lipids. It reduces the levels of triglycerides, very low-
density lipoprotein (VLDL, “bad cholesterol”), and low-
density lipoprotein (LDL, “bad cholesterol”) and
increases high-density lipoprotein (HDL, “good
cholesterol”). Gemfibrozil is an activator of peroxisome
proliferator-activated receptor-alpha (PPARα), a nuclear
receptor important in the metabolism of fats (Fig. 1)
[36–40]. It also regulates adipose tissue differentiation. It
thus promotes the clearance of lipids [35]. A major ad-
vantage is that it is taken orally as a 600 mg tablet twice
a day before meals and has minimal side effects. In fact,
gemfibrozil has been found to have many additional ef-
fects on reducing inflammation, regulating oxidative
stress, promoting signal transduction, increasing myelin-
ation, etc. [40, 41] which have led to many past and
ongoing clinical trials in other disease pathologies
(www.clinicaltrials.gov).
The mechanism of action of Gemfibrozil on
lowering lipids
Fatty acids are metabolized in mitochondria and in per-
oxisomes. While short, medium, and long chain fatty
acids are metabolized in mitochondria, very long chain
fatty acids (VLCFAs) are chain-shortened in peroxi-
somes via peroxisomal β-oxidation. Gemfibrozil being
one of the prototype activators of PPARα stimulates per-
oxisomal β-oxidation by up-regulating the expression of
all three important peroxisomal β-oxidation enzymes
(acyl-CoA oxidase, 2-trans-enoyl-CoA hydratase, and
thiolase) via PPAR-α (Fig. 1) [39, 41]. Since VLCFAs are
major components of LDL and VLDL, a gemfibrozil-
mediated decrease in bad cholesterol (VLDL and LDL)
is directly correlated to increased catabolism of VLCFAs
in peroxisomes.
How does gemfibrozil modulate TPP1?
Gemfibrozil acts in two ways to increase TPP1 in cells
(Fig. 1). Gemfibrozil activates PPARα, which enhances
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the mRNA and protein levels of transcription factor EB
(TFEB) by more than 10-fold and 6-fold, respectively, in
brain cells within 12 h [39]. TFEB then binds to the pro-
moter of genes involved in lysosome biogenesis and acti-
vates their production [43–46]. TFEB can regulate
lysosomes due to its effects on the expression on lyso-
somal genes. All-trans retinoic acid has similar activity.
The combination of all-trans retinoic acid with gemfi-
brozil also enhances TFEB production within 12 h, and
lower doses of both compounds provided maximal activ-
ity in enhancing lysosome biogenesis in brain cells and
in cells derived from patients with CLN2/TPP1 [38].
Gemfibrozil also binds to the retinoid X receptor-α
(RXRα), which binds to PPARα thereby up-regulating
the expression of TPP1 in brain cells via the PPARα/
RXRα heterodimer. Increased TPP1 activity has been
observed in a variety of neuronal cells and fibroblasts
treated with gemfibrozil but not in iPSC cells (Table 1)
[38, 47]. Based on these dual activities, gemfibrozil has
potential for therapeutic applications in the NCLs.
Studies on cells treated with gemfibrozil
Various cells in culture have been treated with gemfibro-
zil (38,47,48) (Table 1). The effect of gemfibrozil on
Cln2 mRNA, protein expression, and TPP1 activity has
been studied in primary mouse neurons and in astro-
cytes and in human astrocytes, and neuronal cells from
different regions of the brain (cortex, hippocampus, stri-
atum, and cerebellum). Gemfibrozil increased the
mRNA for Cln2 with a maximum increase at 24 h in
mouse primary astrocytes [38, 39]. Interestingly the
mRNA for other lysosomal genes, such as Cln1 and
Cln3, were also increased by gemfibrozil. Increased
TPP1 protein was observed inside the cells as well.
Neuronal cells and human astrocytes also showed a
similar response with increased mRNA and protein that
was validated by either western blot, immunofluores-
cence, and/or by a TPP1 activity assay [38]. The effect of
gemfibrozil on TPP1 mRNA was evaluated in wild type,
PPARα deficient, and PPARβ deficient astrocytes isolated
from cells from wild type and genetically modified mice
[39]. Interestingly, gemfibrozil did not increase Cln2
mRNA levels in the cells from the PPARα knock out
(KO) mice whereas the increase in Cln2 mRNA was
seen with gemfibrozil treatment of cells from both wild
type and PPARβ KO mice. Immunofluorescence, western
blot, and an enzyme activity assay confirmed the lack of
Cln2 mRNA up-regulation by gemfibrozil in the cells
isolated from the PPARα KO mice [38]. Similar studies
were done with siRNA-treated cells where there was no
increase in TPP1 with gemfibrozil, and this study further
demonstrated the role of RXRα in regulating the expres-
sion of TPP1 mRNA. These studies confirm the involve-























Fig. 1 Scheme showing the dual mechanism of action of gemfibrozil
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increase in both Cln2 mRNA and TPP1 protein [38]. It
was concluded that gemfibrozil and retinoic acid recruit
both PPARα and RXRα to the RXR-binding site of the
Cln2 gene promoter.
Some studies have been done on cells derived from
NCL patients and models (Table 1) [48, 49]. Lympho-
blasts isolated from control and NCL patients were
investigated for the effect of gemfibrozil on apoptosis,
depolarization of the mitochondrial membrane, and
defective autophagy [49]. NCL (CLN3) lymphoblast cell
viability to normal levels was restored by gemfibrozil in
NCL patient-derived lymphoblasts via decreased apop-
tosis. Furthermore, the high level of membrane potential
depolarization of NCL patient-derived lymphoblasts was
restored to normal levels by gemfibrozil, and defective
autophagy was normalized by gemfibrozil. These find-
ings suggest that gemfibrozil may have a therapeutic
effect by multiple mechanisms for NCL patients [39, 40].
Studies on animals treated with gemfibrozil
The effect of gemfibrozil has been evaluated in a newly
created mouse model of CLN2/TPP1 of NCL (Figure 2)
[49]. This model was created by knocking out the gene
for TPP1. The mice develop progressive motor dysfunc-
tion and die prematurely. A dose of 7.5 mg/kg body
weight of gemfibrozil increased survival by several
weeks to 172 days over that observed with vehicle
alone, 123 days. Furthermore, the mice showed im-
proved motor functions over the controls. Both SOCS3
and IL-Rα are anti-inflammatory factors that are in-
creased with gemfibozil treatment. The anti-apoptotic
molecule phospho-Bad also increased and was coinci-
dent with decreased neuronal loss based on a TUNEL
assay. Finally, a decrease in storage materials in the
motor cortex of the brain was observed in the
gemfibrozil-treated cln2 knock out mice as compared
with the untreated knock out mice [49]. Interestingly,
since these genetically-modified mice lack the cln2
gene, gemfibrozil is likely not working by increasing
TPP1 expression but rather via lysosome biogenesis
and other activities. The findings suggest that gemfibro-
zil can delay the progression of neurodegenerative
decline in an animal model by multiple mechanisms.
Clearly optimizing the dose and frequency of dosing
may further improve the outcome with the animals.
The data also suggest that the neuroprotection by gem-
fibrozil may be applicable to treating children with
CLN2/TPP1 NCL and possible other genetic variants of
the NCLs [48, 49].
When wild type and PPARα and PPARβ KO mice were
analyzed for the effect of gemfibrozil on TPP1
Fig. 2 Summary of the effects of gemfibrozil on the CLN2 knock
out mouse
Table 1 Effect of gemfibrozil on cells and on animals
Treatment Effect Reference
Cells in vitro
Mouse & human primary astrocytes gemfibrozi 25 μm ↑CLN2 mRNA ↑TPP1 protein 38, 39
Mouse neurons from cortex,
striatum & hippocampus
gemfibrozil 25 μm ↑TPP1 protein 38
Lymphoblastic cells from
CLN3 patients
gemfibrozil 25 μm ↑viability ↑autophagy recovery ↑autophagy genes 48
Human IPS models CLN2 and CLN3 mutations gemfibrozil 25 µm No effect on TPP1 47
Animals
Mouse oral gemfibrozil 7.5 mg/kg for 21 d ↑TTP1 in astrocytes, cortical neurons, & non
neural cells of dentate gyrus & CAI of hippocampus
38
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expression, gemfibrozil markedly increased TTP1 pro-
tein expression in the cells of the brains of the wild type
and PPARβ KO mice but not in the PPARα KO mice
[38, 39]. These findings again demonstrate the involve-
ment of PPARα in the gemfibrozil-mediated increase in
TTP1 (38). Furthermore, the Cln2 gene contains an
RXR-binding site, and all-trans retinoic alone can in-
crease TTP1 expression. The studies further confirm
the mechanism of action of gemfibrozil in vivo and
demonstrate the role of the PPARα/RXRα heterodimer
in its activity.
Safety of gemfibrozil: Studies with children
treated with gemfibrozil
Having been approved for human use in 1976, gemfibro-
zil has a long history of safety and tolerability in adults
as a lipid-lowering agent. It has also been used with chil-
dren for various indications (Table 2). In a small study
with 12 children aged 5–17 years who had hyperlipid-
emia with persistent nephrotic syndrome, gemfibrozil
given for 4 months to 7 of the patients (5 were controls)
was found to be effective in improving the lipoprotein
profile of the nephrotic children [50]. Besides efficacy,
gemfibrozil had no side effects, and renal function and
urine protein excretion in this fragile population were
not affected by the treatment. Gemfibrozil was also
given in 2 doses 12 h apart in a study with 97 neonates
(49 treated and 48 control) of at least 34-week gestation
with non-hemolytic jaundice. While there was no change
in the need and duration of phototherapy with the gem-
fibrozil, it was noted that there were no side effects in
the preterm and term neonates [51]. In another pilot
study on 47 pediatric patients with metabolic syndrome,
a dose of 1200 mg/day gemfibrozil for 8 months signifi-
cantly lowered the triglyceride levels and raised the HDL
levels [52]. Two of the patients had muscle pain associ-
ated with the treatment but no other safety issues were
found. Muscle pain was reported as a probable adverse
event in adults. Further, it has been suggested that
fibrates should be considered for children with obesity-
related hyperlipidemias [53]. Two siblings with familial
chylomicronemia syndrome were treated from birth
(oldest child age 7 in the study) and at 6 months of age
(younger child age 4 in the study) with 300 mg gemfi-
brozil twice per day [54]. At 7 and 3.5 years respectively,
there were no side effects from the gemfibrozil, and the
risk of acute pancreatitis, a complication of hyperlipid-
emia, was significantly reduced. There was one case re-
port of an age 13 female patient who developed linear
IgA bullous dermatitis on her areola after 3 weeks on
gemfibrozil, which resolved with drug withdrawal and
steroid treatment [55]. Although side effects have been
reported in adults taking gemfibrozil (Table 3), these are
generally uncommon and rarely severe.
These studies demonstrate that gemfibrozil was well
tolerated and was safe for use in children even with on-
going disease processes. Based on the known drug inter-
actions of gemfibrozil (Table 4), children with NCL
should not be expected to experience problems. How-
ever, with gemfibrozil treatment there may be a potential
reduction in the effectiveness of the anti-convulsive ther-
apies that should be monitored. The off label use of
gemfibrozil in ill children over a range of ages, doses,
and durations suggests that gemfibrozil can be expected
to be safe for use in children with lipid storage diseases.
Summary and conclusions
There are several advantages for use of gemfibrozil in
children with lysosomal storage diseases, NCLs, and in
particular late infantile batten disease CLN2/TPP1.
Gemfibrozil is an oral drug that is not invasive and has
few side effects in adults and in children. Gemfibrozil
has multiple modes of action, and the mechanisms of ac-
tion are known for some of the activities, such as its
ability to increase TPP1 mRNA, protein, and activity, re-
duce inflammation, increase myelination, and increase
lysosome biogenesis [39, 40]. Gemfibrozil can also affect
various signaling pathways involved in switching off T-
helper cells, cell-to-cell contact, migration, apoptosis,
oxidative stress, and inflammation. Finally, using knock
Table 2 Safety of gemfibrozil in children
Age Dose (duration) Purpose Effect Side effects (reference)





n = 2 (52)
Late preterm & term neonates with jaundice
n = 97 (49 active, 48 placebo)
60 mg/kg 2 doses
(1 day)




Infants with Chylomicronemia* Syndrome, n = 2 300 mg 2 x /day
(3, 7 years)
improve jaundice ↓pancreatitis none (54)
Children with hyperlipidemia & nephrotic
syndrome, n=12 (7 active, 5 placebo)





Age 13 female n = 1 3 weeks reduce lipids NA LABD (55)
*Siblings started gemfibrozil at birth and at 6 months, respectively
LABD, linear IgA bullous dermatitis
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out animal models of CLN2/TPP1, gemfibrozil was
found to prolong the lifespan of the animals, decrease
lipid accumulation in the motor cortex, delay the loss of
mobility, and increase certain genes involved in anti-
inflammation and in anti-apoptosis [49]. This neuropro-
tective effects combined with the potential increases in
TPP1 enzyme levels and in biogenesis of lysosomes
suggest that gemfibrozil will have some benefit in treat-
ing early stage children with CLN2/TPP1 and possibly
with other genetic forms of NCLs. The oral administra-
tion is particularly attractive because it is non-invasive
and the safety is well documented. Gemfibrozil could be
used alone or combination with some of the emerging
treatments for these devastating genetic diseases in chil-
dren. One possible limitation might be weight loss that
will need to be monitored since NCL patients have
weight gain issues.
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Table 3 Events related to treatment with gemfibrozil
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SPC (Standard of Product Characteristics) of LOPID® (Gemfibrozil Tablets, USP)
by Pfizer, Revised March 2016






risk of myopathy and rhabdomyolysis
Anticoagulants warfarin dosage should be reduced
CYP2C8 Substrates drugs metabolized CYP2C8 (e.g., dabrafenib,
loperamide, montelukast, paclitaxel, pioglitazone,
rosiglitazone) may be required to reduce
OATP1B1 substrates substrates of OATP1B1 (e.g., atrasentan,
atorvastatin, bosentan, ezetimibe, fluvastatin,
glyburide, SN-38 [active metabolite of irinotecan],
rosuvastatin, pitavastatin, pravastatin, rifampin,
valsartan, olmesartan) may be required to reduce
Bile Acid-Binding
Resins
resin-granule drugs such as colestipol (5 g)
are recommended at 2 or more hours apart
Colchicine myopathy, including rhabdomyolysis in
chronic administration of colchicine
SPC of LOPID issued March.2016
Kim et al. Orphanet Journal of Rare Diseases  (2017) 12:113 Page 7 of 9
Competing interests
HKK and H-JL work for a company that is developing gemfibrozil for use in






1Department of Pharmaceutical Engineering, Inje University, Gimhae, South
Korea. 2Polaryx Therapeutics Inc., Paramus, NJ, USA. 3The George Washington
University Medical Center, Washington, DC, USA. 4Rush University Medical
Center, Chicago, IL, USA.
Received: 24 February 2017 Accepted: 5 June 2017
References
1. Williams RE, Mole SE. New nomenclature and classification scheme for the
neuronal ceroid lipofuscinoses. Neurology. 2012;79:183–91.
2. Mole S, Cotman SL. Genetics of the neuronal ceroid lipofuscinoses (batten
disease). Biochim Biophys Acta. 1852;2015:2237–41.
3. Dolisca SB, Mehta M, Pearce DA, Mink JW, Maria BL. Batten disease: clinical
aspects, molecular mechanisms, translation science and future directions. J
Child Neurol. 2013;28:1074–100.
4. Haltia M, Goebel HH. The neuronal ceroid lipofuscinoses: historical
introduction. Biochim Biophys Acta. 1832;2013:1795–800.
5. Kousi M, Lehesjoki AE, Mole SE. Update of the mutation spectrum and
clinical correlations of over 360 mutations in eight genes that underlie the
neuronal ceroid lipofuscinoses. Hum Mutat. 2012;33:42–63.
6. Carcel-Truillois J. Kovacs, AD, Pearce DA. Cell biology of the NCL proteins:
what they do and don’t do Biochim Biophys Acta. 1852;2015:2242–55.
7. Neverman NJ, Best HL, Hofmann SL, Hughes SM. Experimental therapies in the
neuronal ceroid lipofuscinoses. Biochim Biophys Acta. 1852;2015:2292–300.
8. Geraets RD, Koh SY, Hastings ML, Kielian T, Pearce DA, Weimer JM. Moving
towards effective therapeutic strategies for neuronal ceroid lipofuscinosis.
Orphanet J Rare Dis. 2016;11:40. doi:10.1186/s13023-016-0414-2.
9. Cotman SL, Mole SE, Kohan R. Future perspectives: moving towards NCL
treatments. Biochim Biophys Acta. 1852;2015:2336–8.
10. Sondhi D, Peterson DA, Edelstein AM, del Fierro K, Hackett NR, Crystal RG.
Survival advantage of neonatal CNS gene transfer for late infantile neural
ceroid lipofuscinosis. Exp Neurol. 2008;213:18–27.
11. Worgall S, Sondhi D, Hackett NR, Kosofsky B, Kekatpure MV, Neyzi N, et al.
Treatment of late infantile neuronal ceroid lipofuscinosis by CNS
administration of a serotype 2 adeno-associated virus expressing CLN2
cDAN. Hum Gen Ther. 2008;19:463–74.
12. Sondhi D, Johnson L, Purpura K, Monette S, Souweidande MM, Kaplitt MG,
et al. Long term expression and safety of administration of AAVrh 10hCLN2 to
the brain of rats and nonhuman primates for the treatment of late infantile
neuronal ceroid lipofuscinsis. Hum Gene Ther Methods. 2012;23:324–35.
13. Abordo-Adesida E, Follenzi A, Barcia C, Sciascia S, Castro MG, Naldini L, et al.
Stability of lentiviral vector-mediated transgene expression in the brian in
the presence of systemic antivector immune response. Hum Gene Ther.
2005;16:741–51.
14. Katz ML, Tecedor L, Chen Y, Williamson BG, Lysenko E, Wininger F, et al. AAV
gene transfer delays disease onset in TPP1-deficient canine model of the late
infantile form of batten disease. Sci Transl Med. 2015;7(313):313ra180.
15. Wong AM, Rahim AA, Waddington SN, Cooper JD. Current therapies for the
soluble lysosomal forms of neuronal ceroid lipofuscinosis. Biochem Soc
Trans. 2010;38:1484–8.
16. Chang M, Cooper JD, Sleat DE, Cheng SH, Dodge JC, Passini MA, et al.
Intraventricular enzyme replacement improves disease phenotypes in a mouse
model of late infantile neuronal lipofuscinosis. Mol Ther. 2008;16:649–56.
17. Lu JY, Hu J, Hofmann SL. Human recombinant palmitoyl-protein thioesterase-1
(PPT1) for preclinical evaluation of enzyme replacement therapy for infantile
neuronal ceroid lipofuscinosis. Mol Gener Metab. 2010;99:374–8.
18. Xu S, Wang L, El-Banna M, Schar I, Sleat DE, Lobel P. Large volume
intrathecal delivery increases survival of a mouse model of late infantile
neuronal ceroid lipofuscinosis. Mol Ther. 2011;19:1842–8.
19. Hu J, Lu JY, Wong AM, Hynan LS, Birnbaum SG, Yimaz DS, et al. Intravenous
high dose enzyme replacement therapy with recombinant palmitoyl-
protein thioesterase-1 reduces visceral lysosomal storage and modestly
prolongs survival in a preclinical model of infantile neuronal ceroid
lipofuscinosis. Mol Genet Metab. 2012;107:213–21.
20. Vuillemenot BR, Kennedy D, Cooper JD, Wong AM, Sri S, Doeleman T, et al.
Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in a
canine CLN2 neuronal ceroid lipofuscinosis. Mol Genet Metab. 2014;114:281–93.
21. Katz MI, Coates JR, Sibigtroth CM, Taylor JD, Carpentier M, Young WM, et al.
Enzyme replacement therapy attenuates disease progression in a canine model
of late-infantile ceroid lipofuscinosis (CLN2). J Neurosci Res. 2014;92:1591–8.
22. Dawson G, Schroeder C, Dawson E. Palmitoyl thioesterase (PPT1) inhibitors
can act a pharmacological chaperones in infantile batten disease. Biochim
Biophys Res Commun. 2010;395:66–9.
23. Valenzano KJ, Khanna R, Powe AC, Boyd R, Lee G, Flanagan JJ, et al.
Identification and characterization of pharmacological chaperones for
correct enzyme deficiencies in lysosomal storage disorders. Assay Drug Dev
Technol. 2011;9:213–35.
24. Pears MR, Cooper JD, Mitchinson HM, Mortishire-Smither RJ, Pearce DA,
Griffin JL. High resolution 3H NMR-based metabolomics indicates a
neurotransmitter cycling defect in cerebral tissue from a mouse model of
batten disease. J Biol Chem. 2005;280:42508–14.
25. Kovacs AD, Pearce DA. Attenuation of AMPA receptor activity improves motor
skills in a mouse model of juvenile batten disease. Exp Neurol. 2008;209:288–91.
26. Kovacs AD, Saje A, Wong A, Szenasi G, Kiricsi P, Szabo E, et al. Temporary
inhibition of AMPA receptors induces a prolonged improvement of motor
performance in a mouse model of juvenile batten disease.
Neuropharmacology. 2011;60:405–9.
27. Levin SW, Baker EH, Zein WM, Zhang Z, Quezado ZM, Miao N, et al. Oral
cysteamine bitartrate and N-acetylcysteine for patients with infantile
neuronal ceroid lipofuscinosis: a pilot study. Lancer Neurol. 2014;13:777–87.
28. Seehafer SS, Ramirez-Montealegre D, Wong AM, Chan CH, Castaneda J,
Horak M, et al. Immunosuppression alters disease severity in juvenile batten
disease mice. J Neuroimmunol. 2011;230:169–72.
29. Kay GW, Palmer DN. Chronic oral administration of mimocycline to sheep
with ovine CLN6 neuronal ceroid lipofuscinsis maintsin pharmacological
concentrations in the brain but does not suppress neuroinflammation or
disease progression. J Neuroinflammation. 2013;10:97. doi:10.1186/1742-
2094-10-97.
30. Lake BD, Steward CG, Oakhill A, Wilson J, Perham TG. Bone marrow
transplantation in late infantile batten disease and juvenile batten disease.
Neuropediatrics. 1997;28:80–1.
31. Lonnqvist T, Vanhanen SL. Hematopoietic stem cell transplantation in
infantile neuroid lipofuscinosis. Neurology. 2001;57:1411–6.
32. Tamaki SJ. Jacobs Y, Dohse, Capela a, Cooper JD, Reitsman M, et al.
Neuroprotection of host cells by human central nervous system stem cells
in a mouse model of infantile neuronal ceroid lipofuscinosis. Cell Stem Cell.
2009;5:310–9.
33. Cooper JD, Russell C, Mitchinson HM. Progress towards understanding
disease mechanisms in small vertebrate models of neuronal ceroid
lipofuscinosis. Biochem Bophys Acta. 2006;1762:873–89.
34. Whiting RE, Pearce JW, Castaner LJ, Jensen CA, Katz RJ, Gilliam DH, et al.
Multifocal retinopathy in dachshunds with CLN2 neuronal ceroid
lipofuscinosis. Exp Eye Res. 2015;134:123–32.
35. Rodney G, Uhlendorf P, Maxwell RE. The hypolipemic effect of gemfibrozil
(CL-719) in laboratory animals. Proc R Soc Med. 1976;69(supplement 2):6–10.
36. Jana M, Mondal S, Gonzalez FJ, Pahan K. Gemfibrozil, a lipid-lowering drug,
increases myelin genes in human oligodendrocytes via peroxisome
proliferator-activated receptor-β. J Biol Chem. 2012;287:34134–48.
37. Jana M, Pahan K. Gemfibrozil, a lipid lowering drug, inhibits the activation
of primary human microglia via peroxisome proliferator-activated receptor
β. Neurochem Res. 2012;37:1718–29.
38. Ghosh A, Corbett GT, Gonzalex FJ, Pahan K. Gemfibrozil and fenobrate,
Food and Drug Administration-approved lipid lowering drugs, upregulate
tripeptidyl peptidase 1 in brain cells via peroxisome proliferation activated
receptor α. J Biol Chem. 2012;287:28922–38935.
39. Ghosh A, Jana M, Modi K, Gonzales FJ, Sims K, Berry-Kravis E, et al.
Activation of peroxisome proliferator-activated receptor induces lysosomal
biogenesis in brain cells. J Biol Chem. 2015;290:10309–24.
40. Roy A, Pahan K. Gemfibrozil, stretching arms beyond lipid lowering. Immuno
pharm Immuno Tox. 2009;31:339–51.
Kim et al. Orphanet Journal of Rare Diseases  (2017) 12:113 Page 8 of 9
41. Ashikawa Y, Nishimura Y, Okabe S, Sasagawa S, Murakami S, Yuge M, et al.
Activation of sterol regulatory element binding factors by fenofibrate and
gemfibrozil stimulates myelination in zebrafish. Front Pharmacol. 2016;7:206.
https://doi.org/10.3389/fphar.2016.00206
42. Hashimoto F, Hamada S, Hayahsi H. Effect of gemfibrozil on centrifugal
behavior of rat peroxisomes and activity of peroxiosmal enzymes involved
in lipid metabolism. Biol Pharm Bull. 1997;20:315–21.
43. Sardiello M, Palmieri M, di Ronza A, Medina DL, Valenza M, Gennarino VA, et
al. A gene network regulating lysosomal biogenesis and functions. Science.
2009;325:473–7.
44. Palmieri M, Impey S, Kang D, di Ronza A, Pelz C, Sardiello M, et al.
Characterization of the CLAR network reveals an integrated control of
cellular clearance pathways. Hum Mol Genet. 2011;20:3852–66.
45. Medina DL, Fraldi A, Bouche V, Annunziata F, Mansueto G, Spampanato C,
et al. Transcriptional activation of lysosomal exocytosis promotes cellular
clearance. Dev Cell. 2011;21:421–30.
46. Song W. Wang, Savini M, Ake a, di Ronza a, Sardiello M, et al. TFEB regulates
lysosomal proteostasis. Hum Mol Genet. 2013;22:1994–2009.
47. Lowjewski X, Starpoli JF, Biswas-Legrand S, Simas A, Haliw L, Selig MK, et al.
Human iPSC models of neuronal ceroid lipofuscinosis capture distinct
effects of TPP1 and CLN3 mutations on the endocytic pathway. Huma Mol
Genet. 2014;23:2005–22.
48. Hong M, Song KD, Lee H-K, Yi S, Lee YS, Heo T-H, et al. Fibrates inhibit the
apoptosis of batten disease lymphoblast cells via autophagy recovery and
regulation of mitochondrial membrane potential. In vitro Cell Dev Biol.
2016;52:349–55.
49. Ghosh A, Rangasamy S, Khushbu M, Pahan K. 2016 Gemfibrozil, Food and
Drug Administration-approved lipid-lowering drug, increases longevity in
mouse model of late infantile neuronal ceroid lipofuscinosis. J Neurochem.
2016;14:423–35.
50. Buyukcelik M, Anarat A, Bayazit AK, Noyan A, Ozel A, Anarat R, et al. The
effects of gemfibrozil on hyperlipidemia in children with persistent
nephrotic syndrome. Turk J Pediatr 2002;44:40-44.
51. Jalkrishan PK, Narang A. Gemfibrozil in late preterm and term neonates with
moderate jaundice: a randomized controlled trial. Indian Pediatric.
2009;46:1063–9.
52. Smalley CM, Smalley AB, Goldberg SJ. A pilot study in the efficacy and safety of
gemfibrozil in a pediatric population. J Clin Lipidology. 2008;2:106–11.
53. Kennedy MJ, Jellerson KD, Snow MZ, Zacchetti ML. Challenges in the
pharmacologic management of obesity and secondary dyslipidemia in
children and adolescents. Pediatr Drugs. 2013;15:335–42.
54. Azkawi HA, AlAlwan I. Two siblings with familial chylomiconemia syndrome:
disease course and effectiveness of early treatment. Case Rep Med. 2010;
2010:807434. doi:10.1155/2010/807434.
55. Abtahi-Naeini B, Sadeghiyan H, Adibi N, Shokrollahi MR, Pourazizi M. Bullous
dermatosis of childhood induced by gemfibrozil. J Res Med Sci. 2015;20:207–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Kim et al. Orphanet Journal of Rare Diseases  (2017) 12:113 Page 9 of 9
